OVERVIEW
Radiofrequency Ablation (RFA), is used for patients with Lung Tumors that are ineligible for surgery due to age, presence of co-morbidities or poor general health. RFA is a percutaneously performed procedure that utilizes a small needle electrode which is placed directly into a tumor using a computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound guidance.

PRIOR AUTHORIZATION
Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products

POLICY STATEMENT
Radiofrequency ablation of tumors located in the lung is covered for patients who meet the medical criteria listed below; all other indications are considered not medically necessary due to lack of peer-reviewed literature which supports improved health outcomes.

MEDICAL CRITERIA
Primary non-small-cell lung cancer lesion
Ablation of tumors for local control of primary non-small-cell lung cancer lesion that is no more than 3 cm in size when all of the following criteria is met:
- Surgical resection or radiation treatment with curative intent is considered appropriate based on stage of disease, and
- Medical comorbidity renders the individual unfit for those interventions including chemotherapy;

Non pulmonary tumor(s) metastatic to the lung
Radiofrequency ablation may be considered medically necessary to treat malignant nonpulmonary tumor(s) metastatic to the lung that are no more than 3 cm in size when all of the following criteria are met:
- In order to preserve lung function when surgical resection or radiation treatment is likely to substantially worsen pulmonary status OR the patient is not considered a surgical candidate; AND
- There is no evidence of extrapulmonary metastases; AND the tumor is located at least 1 cm from the trachea, main bronchi, esophagus, aorta, aortic arch branches, pulmonary artery and the heart.
- No more than 3 tumors per lung should be ablated;
- Tumors should be amenable to complete ablation; AND
- Twelve months should elapse before a repeat ablation is considered.

Palliative Care
Ablation of tumors located in the lung for palliative care when all of the criteria below is met:
- The member must have failed radiation and/or chemotherapy, AND
- Not a surgical candidate as deemed by a thoracic surgeon or radiation oncologist.

BACKGROUND
Pulmonary tumors. Surgery is the current treatment of choice in patients with stage 1 primary non-small-cell lung carcinoma (NSCLC). (Stage 1 includes 1a: T1N0M0 and 1b: T2N0M0). Only approximately 20% of patients present with stage 1 disease, although this number is expected to increase as a result of screening programs, advances in imaging modalities, and widespread use of CT scans for other indications. (5)
Postsurgical recurrence rates of stage 1 NSCLC have been reported as between 20% and 30%, with most occurring at distant sites; locoregional recurrences occur in approximately 12%. Large differences in survival outcome are observed after surgery in stage 1 patients, with 5-year overall survival (OS) rates, ranging from 77% for small T1 tumors to 35% for large T2 tumors. Untreated, stage 1 NSCLC has a 5-year OS rate of 6–14%.

RFA is being investigated in patients who are medically inoperable, with small primary lung cancers or lung metastases.

Patients with early stage NSCLC who are not surgical candidates may be candidates for radiation treatment with curative intent. In the 2 largest retrospective radiation therapy series, patients with inoperable disease treated with definitive radiation therapy achieved 5-year survival rates of 10% and 27%. In both studies, patients with T1N0 tumors had better 5-year survival rates of 60% and 32%, respectively.

While available studies are limited by study design, accumulating evidence from case series suggests that RFA may be a treatment option in selected patients with primary, non-small-cell lung cancer and metastatic pulmonary tumors. Although complications have been reported with the use of RFA in the lung, evidence suggests RFA may have survival rates and have rates of procedure-related complications and mortality similar to surgery. Surgical resection remains the treatment of choice, but in patients unable to tolerate surgery due to medical comorbidities, RFA may be considered a treatment option.

COVERAGE
Benefits vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable surgery services and services not medically necessary coverage.

CODING
BlueCHiP for Medicare and Commercial
The following CPT Code is medically necessary when medical criteria above is met:
32998:

RELATED POLICIES
None

PUBLISHED
Provider Update Aug 2014
Provider Update Sep 2012
Provider Update Aug 2011
Provider Update, Aug 2010

REFERENCES


Percutaneous Radiofrequency Ablation of Malignancies in the Lung
Damian E. Dupuy¹, Ronald J. Zagoria², Wallace Akerley¹, William W. Mayo-Smith¹, Peter V. Kavanagh² and Howard Safran³


Zhu JC, Yan TD, Ng K, Glenn D, Morris DL. Percutaneous Radiofrequency Ablation of Lung Tumours: Results in First 100 Consecutive Patients, J Clin Oncol (Meeting Abstracts) 2007 25: 7714.

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.